Recent Updates
Recently added Catalysts
CORT Positive Sentiment

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)

Friday, September 18, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Corcept Therapeutics announced that the CHMP has recommended the approval of relacorilant for marketing authorization in the European Union. This recommendation is a significant step towards making the drug available to patients in Europe. The approval could enhance Corcept's market presence and support its mission to treat severe disorders.

Market Sentiment Analysis

POSITIVE FACTORS

  • CHMP has recommended approval for relacorilant.
  • Potential for expanded market access in the EU.
  • Corcept Therapeutics is progressing in its drug development.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+283%
120-day peak, hindsight
Typical move
3.6%
average across 6 past catalysts
Lead asset
Relacorilant
Phase 2 · Adenocarcinoma

Full Press Release Details

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined wit

Frequently Asked Questions

What is the CHMP's recommendation for relacorilant?

The CHMP has recommended that the European Commission approve relacorilant.

What company is behind relacorilant?

Corcept Therapeutics Incorporated is the company developing relacorilant.

What disorders does Corcept aim to treat?

Corcept focuses on severe endocrinologic, oncologic, metabolic, and neurologic disorders.

What does the CHMP's opinion mean for Corcept?

The CHMP's opinion is a significant step towards obtaining marketing authorization in the EU.

ShareAdd on Google
Tags: CORT Viatris Investor Conferences Healthcare Corcept Therapeutics relacorilant CHMP EU marketing authorization
Last updated: Sep 18, 2026

Biotech snapshot

Cash runway
$545M liquidity · $0M/mo burn
Low dilution risk
Lead asset
RelacorilantPhase 2
Adenocarcinoma →

Catalyst track record

+283%
best trade around CORT's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for CORT.

See every catalyst's timing & PoA →